Wall Street brokerages expect Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to post earnings per share (EPS) of ($1.26) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Alder Biopharmaceuticals’ earnings. The lowest EPS estimate is ($1.37) and the highest is ($1.07). Alder Biopharmaceuticals posted earnings per share of ($1.99) in the same quarter last year, which indicates a positive year over year growth rate of 36.7%. The business is expected to report its next earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Alder Biopharmaceuticals will report full-year earnings of ($4.24) per share for the current year, with EPS estimates ranging from ($5.18) to ($3.64). For the next financial year, analysts expect that the company will report earnings of ($3.22) per share, with EPS estimates ranging from ($4.26) to ($2.30). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Alder Biopharmaceuticals.
Alder Biopharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.03) by $0.23. The firm had revenue of $0.94 million during the quarter. During the same period last year, the firm earned ($0.97) earnings per share.
Shares of Alder Biopharmaceuticals (NASDAQ:ALDR) opened at $14.90 on Tuesday. Alder Biopharmaceuticals has a 52-week low of $8.60 and a 52-week high of $24.10. The stock has a market cap of $1,010.00, a PE ratio of -2.87 and a beta of 2.51.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC purchased a new position in Alder Biopharmaceuticals in the fourth quarter valued at about $351,000. Palo Alto Investors LLC boosted its stake in Alder Biopharmaceuticals by 2,757.5% in the fourth quarter. Palo Alto Investors LLC now owns 1,840,246 shares of the biopharmaceutical company’s stock valued at $21,071,000 after acquiring an additional 1,775,846 shares during the last quarter. Redmile Group LLC boosted its stake in Alder Biopharmaceuticals by 0.4% in the fourth quarter. Redmile Group LLC now owns 6,505,766 shares of the biopharmaceutical company’s stock valued at $74,491,000 after acquiring an additional 29,000 shares during the last quarter. Crestline Management LP purchased a new position in Alder Biopharmaceuticals in the fourth quarter valued at about $1,519,000. Finally, Millennium Management LLC purchased a new position in Alder Biopharmaceuticals in the fourth quarter valued at about $2,341,000. Hedge funds and other institutional investors own 99.14% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by American Banking News and is the property of of American Banking News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.americanbankingnews.com/2018/03/13/brokerages-expect-alder-biopharmaceuticals-inc-aldr-to-announce-1-26-eps.html.
Alder Biopharmaceuticals Company Profile
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.